AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20494902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 311
Study 20494902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Atorvastatin
Number of subjects: 311
Study 16919926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg/day
Number of subjects: 80
Study 16919926 — intervention group
Group type: COMPARATOR
Intervention: Oxitropium 800 mcg/day
Number of subjects: 80
Study 15613428 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mug)
Number of subjects: 931
Study 15613428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study 12214543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement of live Lactobacillus acidophilus and Lactobacillus Casei, 10(7)‐10(8)/ml in fermented milk (LB)
Number of subjects: 100
Study 12214543 — intervention group
Group type: COMPARATOR
Intervention: Fluid milk (L) as control
Number of subjects: 100
Study 9626806 — intervention group
Group type: COMPARATOR
Intervention: rhGM-CSF
Number of subjects: 51
Study 9626806 — intervention group
Group type: COMPARATOR
Intervention: rhG-CSF
Number of subjects: 51
Study 9626806 — intervention group
Group type: COMPARATOR
Intervention: No cytokines
Number of subjects: 51
Study 7710150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aerosolized glycopyrrolate
Number of subjects: 57
Study 7710150 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized placebo
Number of subjects: 57
Study 2651013 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex (Rumalon), administered as intramuscular injections of 3 x 2 ml ampoules per week for 8 weeks, alternating with 8-week periods free of trial medication
Number of subjects: 62
Study 2651013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2651013 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex (Rumalon)
Number of subjects: 62
Study 646918 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 0
Study 646918 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 0
Study 646918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Extradural and General anaesthesia)
Number of subjects: 0
Study 30859297 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil® (collagen-fibrin sealant patch)
Number of subjects: 19
Study 30859297 — intervention group
Group type: COMPARATOR
Intervention: Standard closure without collagen-fibrin sealant patch
Number of subjects: 19
Study 27973336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA) as post-implantation antithrombotic treatment
Number of subjects: 107
Study 25923820 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Injection (SI)
Number of subjects: 100
Study 25923820 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-Injection (TI)
Number of subjects: 100
Study 25923820 — intervention group
Group type: COMPARATOR
Intervention: Both SI and TI
Number of subjects: 100
Study 22129607 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine (V‐A) 160/5 mg
Number of subjects: 60
Study 22129607 — intervention group
Group type: COMPARATOR
Intervention: Valsartan + Hydrochlorothiazide (V‐H) 160/12.5 mg
Number of subjects: 60
Study 20514078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem coadministered with tacrolimus in CYP3A5 expressers
Number of subjects: 0
Study 20514078 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided dosing for CYP3A5 expressers
Number of subjects: 0
Study 20514078 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing for CYP3A5 nonexpressers
Number of subjects: 0
Study 19892046 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory CK-MB values
Number of subjects: 913
Study 19892046 — intervention group
Group type: COMPARATOR
Intervention: Site-reported CK-MB values
Number of subjects: 913
Study 19892046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MI (core and site laboratory)
Number of subjects: 913
Study 19892046 — intervention group
Group type: COMPARATOR
Intervention: Patients without MI (core or site laboratory)
Number of subjects: 913
Study 19892046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MI (core laboratory but not site laboratory)
Number of subjects: 913
Study 16672036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersed housing in the community
Number of subjects: 60
Study 16672036 — intervention group
Group type: COMPARATOR
Intervention: Cluster centres
Number of subjects: 60
Study 15243853 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser with dosage of 3 J/per painful point
Number of subjects: 60
Study 15243853 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser with dosage of 1.5 J/per painful point
Number of subjects: 60
Study 15243853 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 60
Study 11305843 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clozapine (mean daily dose of 630 mg)
Number of subjects: 45
Study 11305843 — intervention group
Group type: COMPARATOR
Intervention: Clozaril (mean daily dose of 610 mg)
Number of subjects: 45
Study 9039090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 to 0.2 microgram/kg per minute)
Number of subjects: 24
Study 9039090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 24
Study 7904847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 59
Study 7904847 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 59
Study 7904847 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (CBS, tetracycline and metronidazole)
Number of subjects: 59
Study 7904847 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 59
Study 3323596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (mean 1.5 mg/kg/day) for 23 +/- 4 months
Number of subjects: 26
Study 3323596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide treatment
Number of subjects: 26
Study 3323596 — intervention group
Group type: COMPARATOR
Intervention: Control (no cyclophosphamide)
Number of subjects: 26
Study 29703585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises progression
Number of subjects: 139
Study 27182016 — intervention group
Group type: EXPERIMENTAL
Intervention: K-MBSR program (8 sessions, once a week, 2.5 hours each)
Number of subjects: 52
Study 24177203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg bid for 16 weeks
Number of subjects: 35
Study 24177203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22407134 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-food odorant (jasmine)
Number of subjects: 67
Study 22407134 — intervention group
Group type: COMPARATOR
Intervention: Food odorant (green apple)
Number of subjects: 67
Study 22407134 — intervention group
Group type: COMPARATOR
Intervention: Control odorant (water)
Number of subjects: 67
Study 20691354 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 64
Study 20691354 — intervention group
Group type: COMPARATOR
Intervention: Dynamax appliance
Number of subjects: 64
Study 18347003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment by partial hospitalization
Number of subjects: 41
Study 16238654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser-MTA pulpotomy
Number of subjects: 16
Study 16238654 — intervention group
Group type: COMPARATOR
Intervention: Formocresol-ZOE pulpotomy
Number of subjects: 16
Study 12405169 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days ceftriaxone therapy
Number of subjects: 73
Study 12405169 — intervention group
Group type: COMPARATOR
Intervention: 10 days ceftriaxone therapy
Number of subjects: 73
Study 10375084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (CMT) consisting of radiation therapy (RT) and chemotherapy (CT)
Number of subjects: 0
Study 10375084 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 0
Study 10375084 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 0
Study 7714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 12
Study 2402811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with propofol-fentanyl (Group I)
Number of subjects: 40
Study 2402811 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl anaesthesia with a supplement of nitrous oxide (Group II)
Number of subjects: 40
Study 2402811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 40
Study 7358202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propranolol and bendrofluazide tablets given twice daily
Number of subjects: 14
Study 7358202 — intervention group
Group type: COMPARATOR
Intervention: Combined capsule of propranolol and bendrofluazide given twice daily
Number of subjects: 14
Study 31088143 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based multisensory stimulation and environmental enrichment intervention
Number of subjects: 30
Study 31088143 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 25658017 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic sleep restriction (4 hours time in bed)
Number of subjects: 14
Study 25658017 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (8 hours time in bed)
Number of subjects: 14
Study 23907451 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroplasty patients with complaints
Number of subjects: 200
Study 23907451 — intervention group
Group type: COMPARATOR
Intervention: Symptom-free patients
Number of subjects: 200
Study 21776546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and early anterior cruciate ligament reconstruction (median of 44.5 days after the injury)
Number of subjects: 61
Study 21776546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and delayed anterior cruciate ligament reconstruction (408 days)
Number of subjects: 61
Study 21776546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation alone
Number of subjects: 61
Study 21776546 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 61
Study 18830236 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine dose escalation (30-50 mg per day as tolerable)
Number of subjects: 107
Study 18830236 — intervention group
Group type: COMPARATOR
Intervention: Placebo dose escalation (paroxetine 20 mg per day + placebo)
Number of subjects: 107
Study 18830236 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine dose escalation
Number of subjects: 107
Study 18830236 — intervention group
Group type: COMPARATOR
Intervention: Placebo dose escalation
Number of subjects: 107
Study 16921503 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 154
Study 16921503 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 154
Study 16921503 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 154
Study 16921503 — intervention group
Group type: COMPARATOR
Intervention: Control group (blood bank donors)
Number of subjects: 154
Study 12846847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-substituted chewing gums
Number of subjects: 892
Study 12846847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 892
Study 12846847 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 892
Study 10364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 60
Study 10364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Number of subjects: 60
Study 10364988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 8909670 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 25
Study 8909670 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 25
Study 8909670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 25
Study 8909670 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 25
Study 1905998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gorging pattern (2 meals per day)
Number of subjects: 13
Study 1905998 — intervention group
Group type: COMPARATOR
Intervention: Nibbling pattern (7 meals per day)
Number of subjects: 13
Study 6308063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3900 mg per day)
Number of subjects: 72
Study 6308063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ascorbic acid 1500 mg per day)
Number of subjects: 72
Study 31088505 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwifery continuity of care intervention
Number of subjects: 350
Study 31088505 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 350
Study 30526440 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood pleurodesis (ABP)
Number of subjects: 123
Study 30526440 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 123
Study 26859491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (target SBP <140 mmHg)
Number of subjects: 1997
Study 26859491 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure treatment (SBP <180 mmHg)
Number of subjects: 1997
Study 25147350 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually defined, targeted physical therapy program
Number of subjects: 10
Study 25147350 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy program
Number of subjects: 10
Study 21861071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted right hemicolectomy (LARH)
Number of subjects: 145
Study 21861071 — intervention group
Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORH)
Number of subjects: 145
Study 19282241 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 202638
Study 19282241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (USS)
Number of subjects: 202638
Study 19282241 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 202638
Study 17517480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (4/1, 8/2, 16/4, 32mg/8mg)
Number of subjects: 16
Study 17517480 — intervention group
Group type: EXPERIMENTAL
Intervention: Split doses of buprenorphine/naloxone (50% of the dose that precipitated withdrawal)
Number of subjects: 16
Study 17517480 — intervention group
Group type: COMPARATOR
Intervention: Full doses of buprenorphine/naloxone (100% of the dose that precipitated withdrawal)
Number of subjects: 16
Study 17517480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17517480 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone (0.2mg)
Number of subjects: 16
Study 17517480 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (100mg)
Number of subjects: 16
Study 16387079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo PGE1 therapy
Number of subjects: 40
Study 16387079 — intervention group
Group type: COMPARATOR
Intervention: Control (no Lipo PGE1 therapy)
Number of subjects: 40
Study 12218339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated dialyzer
Number of subjects: 30
Study 12218339 — intervention group
Group type: COMPARATOR
Intervention: Acrylonitrile dialyzer
Number of subjects: 30
Study 12218339 — intervention group
Group type: COMPARATOR
Intervention: Polysulphone dialyzer
Number of subjects: 30
Study 9469999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 55)
Number of subjects: 109
Study 9469999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 109
Study 7619668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg daily
Number of subjects: 9
Study 7619668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 9
Study 7619668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 9
Study 7619668 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin
Number of subjects: 9
Study 7619668 — intervention group
Group type: COMPARATOR
Intervention: Control group 1: Long-term enalapril treatment with no cough (n = 18)
Number of subjects: 9
Study 7619668 — intervention group
Group type: COMPARATOR
Intervention: Control group 2: Nifedipine (n = 17)
Number of subjects: 9
Study 2404072 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune DLE
Number of subjects: 14
Study 2404072 — intervention group
Group type: COMPARATOR
Intervention: Nonimmune DLE
Number of subjects: 14
Study 2404072 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune DLE (subsequent treatment)
Number of subjects: 14
Study 31723956 — intervention group
Group type: EXPERIMENTAL
Intervention: Betacyanin-rich supplement of Opuntia stricta
Number of subjects: 48
Study 31723956 — intervention group
Group type: EXPERIMENTAL
Intervention: Betalain-rich supplement of red beetroot
Number of subjects: 48
Study 31723956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29019951 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein nutritional support (ONS)
Number of subjects: 114
Study 29019951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high protein nutritional support)
Number of subjects: 114
Study 26057135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap5 (2.5μg)
Number of subjects: 705
Study 26057135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap1 (20μg)
Number of subjects: 705
Study 26057135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tdap5 and Tdap1
Number of subjects: 705
Study 23527804 — intervention group
Group type: EXPERIMENTAL
Intervention: SPDJCS (n=65)
Number of subjects: 165
Study 23527804 — intervention group
Group type: COMPARATOR
Intervention: End-to-end/end-to-side invaginated anastomosis (Group A, n=52)
Number of subjects: 165
Study 23527804 — intervention group
Group type: COMPARATOR
Intervention: End-to-side mucosal anastomosis (Group B, n=48)
Number of subjects: 165
Study 23527804 — intervention group
Group type: COMPARATOR
Intervention: Group A and Group B (n=100 combined)
Number of subjects: 165
Study 21512490 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopran
Number of subjects: 0
Study 19332722 — intervention group
Group type: EXPERIMENTAL
Intervention: ixabepilone plus capecitabine
Number of subjects: 0
Study 19332722 — intervention group
Group type: COMPARATOR
Intervention: capecitabine alone
Number of subjects: 0
Study 16844449 — intervention group
Group type: EXPERIMENTAL
Intervention: AESOP
Number of subjects: 20
Study 16844449 — intervention group
Group type: COMPARATOR
Intervention: EndoAssist
Number of subjects: 20
Study 16844449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both robots
Number of subjects: 20
Study 14599971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Octreotide (TAM+OCT)
Number of subjects: 39
Study 14599971 — intervention group
Group type: COMPARATOR
Intervention: Regular chemotherapeutic agents (5‐Fu and MMC)
Number of subjects: 39
Study 10903022 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (PC) 400 mg
Number of subjects: 20
Study 10903022 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 8792792 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization in large studies
Number of subjects: 0
Study 8792792 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention and postintervention design
Number of subjects: 0
Study 8792792 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmeasured patient/error variance
Number of subjects: 0
Study 1451519 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 1 mg/ethinyl estradiol 35 micrograms (NET/EE)
Number of subjects: 58
Study 1451519 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms (LNG/EE)
Number of subjects: 58
Study 1451519 — intervention group
Group type: COMPARATOR
Intervention: Control group (IUD)
Number of subjects: 58
Study 6328298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times daily
Number of subjects: 143
Study 6328298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg twice daily
Number of subjects: 143
Study 6328298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 30209575 — intervention group
Group type: EXPERIMENTAL
Intervention: Single crown group (190 crowns)
Number of subjects: 233
Study 30209575 — intervention group
Group type: EXPERIMENTAL
Intervention: Retainer crown group (276 retainer crowns)
Number of subjects: 233
Study 29424490 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) 25% for 2 years
Number of subjects: 218
Study 29424490 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum control (AL)
Number of subjects: 218
Study 27824606 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 18
Study 27824606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24491079 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention
Number of subjects: 67
Study 24491079 — intervention group
Group type: COMPARATOR
Intervention: Distractor task
Number of subjects: 67
Study 22139613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection and panretinal photocoagulation (PRP)
Number of subjects: 19
Study 22139613 — intervention group
Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 19
Study 20068257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium
Number of subjects: 68517
Study 20068257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D alone (10 microg or 20 microg)
Number of subjects: 68517
Study 17414400 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand candidate vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Number of subjects: 332